Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective

Drug Discovery Today

Volumn 21, Issue 10, 2016, Pages 1699-1710

  Ferreira, Leonardo G ^a   Andricopulo, Adriano D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIBIOTIC AGENT; ANTILEISHMANIAL AGENT; ANTINEOPLASTIC AGENT; CLEMASTINE; CLOFAZIMINE; CLOMIPRAMINE; DORAMECTIN; ESTROGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; POSACONAZOLE; PROTEIN TYROSINE KINASE; PSYCHOTROPIC AGENT; RALOXIFENE; STEROL 14ALPHA DEMETHYLASE; STEROL 14ALPHA DEMETHYLASE INHIBITOR; TAFENOQUINE;

AFRICAN TRYPANOSOMIASIS; BACTERIAL GROWTH; CHAGAS DISEASE; CLINICAL TRIAL (TOPIC); DRUG POTENTIATION; DRUG REPOSITIONING; HEART MUSCLE FIBROSIS; HUMAN; IN VIVO STUDY; LEISHMANIASIS; MEDICINAL CHEMISTRY; NEGLECTED DISEASE; NEGLECTED TROPICAL DISEASE; NONHUMAN; PARASITE VIABILITY; PARASITOSIS; REVIEW; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; TROPICAL DISEASE; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; WORM; ANIMAL; TROPICAL MEDICINE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG REPOSITIONING; HUMANS; NEGLECTED DISEASES; PARASITIC DISEASES; TROPICAL MEDICINE;

EID: 84979665750     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.06.021     Document Type: Review

References (77)

1. 1 Fenwick, A., The global burden of neglected tropical diseases. Public Health 126 (2012), 233–236.
2. 2 Jakobsen, P.H., et al. Innovative partnerships for drug discovery against neglected diseases. PLoS Negl. Trop. Dis., 5, 2011, e1221.
3. 3 Linehan, M., et al. Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: proving the feasibility at national scale. Am. J. Trop. Med. Hyg. 84 (2011), 5–14.
4. 4 Goupil, L.S., McKerrow, J.H., Introduction: drug discovery and development for neglected diseases. Chem. Rev. 114 (2014), 11131–11137.
5. 5 Chatelain, E., Chagas disease drug discovery: toward a new era. J. Biomol. Screen. 20 (2015), 22–35.
6. 6 Caffrey, C.R., Secor, W.E., Schistosomiasis: from drug deployment to drug development. Curr. Opin. Infect. Dis. 24 (2011), 410–417.
7. 7 Zhou, Y., et al. The Schistosoma japonicum genome reveals features of host–parasite interplay. Nature 460 (2009), 345–351.
8. 8 El-Sayed, N.M., et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309 (2005), 409–415.
9. 9 Berriman, M., et al. The genome of the African trypanosome Trypanosoma brucei. Science 309 (2005), 416–422.
10. 10 Ivens, A.C., et al. The genome of the kinetoplastid parasite, Leishmania major. Science 309 (2005), 436–442.
11. 11 Cohen, J.P., et al. Measuring progress in neglected disease drug development. Clin. Ther. 36 (2014), 1037–1042.
12. 12 Andrews, K.T., et al. Drug repurposing and human parasitic protozoan diseases. Int. J. Parasitol. Drugs Drug Resist. 4 (2014), 95–111.
13. 13 Langedijk, J., et al. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov. Today 20 (2015), 1027–1034.
14. 14 Pollastri, M.P., Campbell, R.K., Target repurposing for neglected diseases. Future Med. Chem. 3 (2011), 1307–1315.
15. 15 Sykes, M.L., Avery, V.A., Protozoan drug discovery: phenotypic screening. J. Med. Chem. 56 (2013), 7727–7740.
16. 16 De Rycker, M., et al. Identification of trypanocidal activity for known clinical compounds using a new Trypanosoma cruzi hit-discovery screening cascade. PLoS Negl. Trop. Dis., 10, 2016, e0004584.
17. 17 Gilbert, I.H., Drug discovery for neglected diseases: molecular target-based and phenotypic approaches. J. Med. Chem. 56 (2013), 7719–7726.
18. 18 Novac, N., Challenges and opportunities of drug repositioning. Trends Pharmacol. Sci. 34 (2013), 267–272.
19. 19 Dent, J., et al. WIPO Re:Search: a consortium catalyzing research and product development for neglected tropical diseases. Pharm. Pat. Anal. 2 (2013), 591–596.
20. 20 Montgomery, S.P., et al. Neglected parasitic infections in the United States: Chagas disease. Am. J. Trop. Med. Hyg. 90 (2014), 814–818.
21. 21 Muñoz, M.J., et al. The urgent need to develop new drugs and tools for the treatment of Chagas disease. Expert Rev. Anti Infect. Ther. 9 (2011), 5–7.
22. 22 Castro, J.A., et al. Toxic side effects of drugs used to treat Chagas’ disease (American trypanosomiasis). Hum. Exp. Toxicol. 25 (2006), 471–479.
23. 23 Bahia, M.T., et al. Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl. Trop. Dis., 6, 2012, e1870.
24. 24 Choi, J.Y., et al. Drug strategies targeting CYP51 in neglected tropical diseases. Chem. Rev. 114 (2014), 11242–11271.
25. 25 Veiga-Santos, P., et al. Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi. Int. J. Antimicrob. Agents 40 (2012), 61–71.
26. 26 Diniz, L., et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob. Agents Chemother. 54 (2010), 2979–2986.
27. 27 Olivieri, B.P., et al. A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Int. J. Antimicrob. Agents 36 (2010), 79–83.
28. 28 Bahia, M.T., et al. Therapeutic approaches under investigation for treatment of Chagas disease. Expert Opin. Investig. Drugs 23 (2014), 1225–1237.
29. 29 Benson, T.J., et al. Rationally designed selective inhibitors of trypanothione reductase phenothiazines and related tricyclics as lead structures. Biochem. J. 286 (1992), 9–11.
30. 30 Flohé, L., The trypanothione system and its implications in the therapy of trypanosomatid diseases. Int. J. Med. Microbiol. 302 (2012), 216–220.
31. 31 Fauro, R., et al. Use of clomipramine as chemotherapy of the chronic phase of Chagas disease. Parasitology 140 (2013), 917–927.
32. 32 Planer, J.D., et al. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi. PLoS Negl. Trop. Dis., 8, 2014, e2977.
33. 33 Colley, D.G., et al. Human schistosomiasis. Lancet 383 (2014), 2253–2264.
34. 34 Ezeamama, A.E., et al. Treatment for Schistosoma japonicum, reduction of intestinal parasite load, and cognitive test score improvements in school-aged children. PLoS Negl. Trop. Dis., 6, 2012, e1634.
35. 35 Gray, D.J., et al. Diagnosis and management of schistosomiasis. BMJ, 342, 2011, d2651.
36. 36 Thétiot-Laurent, S.A.L., et al. Schistosomiasis chemotherapy. Angew. Chem. Int. Ed. Engl. 52 (2013), 7936–7956.
37. 37 Nwaka, S., Hudson, A., Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5 (2006), 941–955.
38. 38 Berriman, M., et al. The genome of the blood fluke Schistosoma mansoni. Nature 460 (2009), 352–358.
39. 39 Istvan, E.S., Deisenhofer, J., Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292 (2001), 1160–1164.
40. 40 Rojo-Arreola, L., et al. Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS ONE, 9, 2014, e87594.
41. 41 Chen, G.Z., et al. Antischistosomal action of mevinolin: evidence that 3-hydroxy-methylglutaryl-coenzyme a reductase activity in Schistosoma mansoni is vital for parasite survival. Naunyn Schmiedebergs Arch. Pharmacol. 342 (1990), 477–482.
42. 42 Gelmedin, V., et al. Re-positioning protein-kinase inhibitors against schistosomiasis. Future Med. Chem. 7 (2015), 737–752.
43. 43 Beckmann, S., et al. Schistosoma mansoni: signal transduction processes during the development of the reproductive organs. Parasitology 137 (2010), 497–520.
44. 44 Beckmann, S., et al. Characterization of the Src/Abl hybrid kinase SmTK6 of Schistosoma mansoni. J. Biol. Chem. 286 (2011), 42325–42336.
45. 45 Buro, C., et al. Imatinib treatment causes substantial transcriptional changes in adult Schistosoma mansoni in vitro exhibiting pleiotropic effects. PLoS Negl. Trop. Dis., 8, 2014, e2923.
46. 46 Beckmann, S., et al. Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor imatinib. Int. J. Parasitol. Drugs Drug Resist. 4 (2014), 287–295.
47. 47 Cowan, N., Keiser, J., Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni. Parasit. Vectors, 8, 2015, 417.
48. 48 Panic, G., et al. Activity profile of an FDA-approved compound library against Schistosoma mansoni. PLoS Negl. Trop. Dis., 9, 2015, e0003962.
49. 49 Taman, A., et al. Evaluation of the in vivo effect of ivermectin on Schistosoma mansoni in experimentally-infected mice. J. Coast. Life Med. 2 (2014), 817–823.
50. 50 Brun, R., Blum, J., Human African trypanosomiasis. Infect. Dis. Clin. North Am. 26 (2012), 261–273.
51. 51 Lejon, V., et al. Human African trypanosomiasis. Handb. Clin. Neurol. 114 (2013), 169–181.
52. 52 Simarro, P.P., et al. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology 139 (2012), 842–846.
53. 53 Barrett, M.P., et al. Drug resistance in human African trypanosomiasis. Future Microbiol. 6 (2011), 1037–1047.
54. 54 Abeloff, M.D., et al. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer. Cancer Treat. Rep. 70 (1986), 843–845.
55. 55 Alirol, E., et al. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo. Clin. Infect. Dis. 56 (2013), 195–203.
56. 56 Kaiser, M., et al. Antiprotozoal activity profiling of approved drugs: a starting point toward drug repositioning. PLoS ONE, 10, 2015, e0135556.
57. 57 Price, R.N., Nosten, F., Single-dose radical cure of Plasmodium vivax: a step closer. Lancet 383 (2014), 1020–1021.
58. 58 Carvalho, L., et al. The Oral antimalarial drug tafenoquine shows activity against Trypanosoma brucei. Antimicrob. Agents Chemother. 59 (2015), 6151–6160.
59. 59 Zhou, L., et al. A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro. J. Med. Chem. 56 (2013), 796–806.
60. 60 Wyllie, S., et al. Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei. J. Antimicrob. Chemother. 71 (2016), 625–634.
61. 61 Alvar, J., et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE, 7, 2012, e35671.
62. 62 Nagle, A.S., et al. Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. Chem. Rev. 114 (2014), 11305–11347.
63. 63 Petri, W.A. Jr., Therapy of intestinal protozoa. Trends Parasitol. 19 (2003), 523–526.
64. 64 Wong-Beringer, A., et al. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27 (1998), 603–618.
65. 65 Sindermann, H., et al. Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med. Microbiol. Immunol. 193 (2004), 173–180.
66. 66 No, J.H., Visceral leishmaniasis: revisiting current treatments and approaches for future discoveries. Acta Trop. 155 (2016), 113–123.
67. 67 Merritt, C., et al. Kinases as druggable targets in trypanosomatid protozoan parasites. Chem. Rev. 114 (2014), 11280–11304.
68. 68 Ruiter, G.A., et al. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 14 (2003), 167–173.
69. 69 van Blitterswijk, W.J., Verheij, M., Anticancer mechanisms and clinical application of alkylphospholipids. Biochim. Biophys. Acta 1831 (2013), 663–674.
70. 70 Cleghorn, L.A., et al. Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3. ChemMedChem 6 (2011), 2214–2224.
71. 71 Sanderson, L., et al. Activity of anti-cancer protein kinase inhibitors against Leishmania spp. J. Antimicrob. Chemother. 69 (2014), 1888–1891.
72. 72 Karaman, M.W., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26 (2008), 127–132.
73. 73 Maximov, P.Y., et al. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr. Clin. Pharmacol. 8 (2013), 135–155.
74. 74 Buzdar, A.U., et al. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45 (1988), 344–345.
75. 75 Miguel, D.C., et al. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J. Antimicrob. Chemother. 63 (2009), 365–368.
76. 76 Reimão, J.Q., et al. Antileishmanial activity of the estrogen receptor modulator raloxifene. PLoS Negl. Trop. Dis., 8, 2014, e2842.
77. 77 Jin, G., Wong, S.T., Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov. Today 19 (2014), 637–644.